Sanofi (SNY)

45.10
NYSE : Health Technology
Prev Close 44.57
Day Low/High 44.77 / 45.30
52 Wk Low/High 37.43 / 46.25
Avg Volume 1.38M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 110.86B
EPS 1.70
P/E Ratio 23.96
Div & Yield 1.20 (2.81%)
Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets closed near session highs Monday.

Philippine FDA Says Sanofi of Knew of Vaccine's Dangers in 2015

Philippine FDA Says Sanofi of Knew of Vaccine's Dangers in 2015

The Philippine government says Sanofi knew that the vaccine should not have been given to people who have never had dengue fever.

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

The charges were related to an interest-rate problem.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: OMC, WMS Downgrades: ALSK, ATV, BP, CARB, CMP, CRL, DAN, FRT, SNY, VNO, WU, ZIXI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

A steeper fall might cause both buyers and sellers to re-think potential deals, but so far that doesn't seem to be the case yet.

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.

Nationalized 5G and Everything Else You Need to Know Before You Trade Monday

Nationalized 5G and Everything Else You Need to Know Before You Trade Monday

As the Trump administration reportedly considers government controlled 5G, investors prepare for a hectic week of earnings.

Tax Reform's Impact on the Economy

Tax Reform's Impact on the Economy

Consumer spending should be more than solid given wage increases.

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.

Allergan and Energy Stocks Have Big Days

A flurry of high-priced merger-and-acquisition activity explains the move in Allergan.

Dow, S&P 500 and Nasdaq Post New Records as Senate Reaches Deal to End Shutdown

Dow, S&P 500 and Nasdaq Post New Records as Senate Reaches Deal to End Shutdown

Stocks hit fresh records on Monday after a deal is reached to end the three-day government shutdown.

Dow, S&P 500 and Nasdaq Shake Off Government Shutdown to Trade Higher

Dow, S&P 500 and Nasdaq Shake Off Government Shutdown to Trade Higher

Stocks turn higher on Monday, as investors watch for the impact of a federal government shutdown that entered its third day.

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?

Will the Government Shutdown Kill the Mind-Blowing Bull Market?

Will the Government Shutdown Kill the Mind-Blowing Bull Market?

The stock market's impressive start to the year is at risk as the government shutdown enters day three. Meanwhile, a series of healthcare deals captivates Wall Street's attention.

Government Shutdown and Everything Else You Need to Know Monday Morning

Government Shutdown and Everything Else You Need to Know Monday Morning

So what does a government shutdown mean for today's trading? Here's what you need to know before Monday's opening bell.

Shutdown Enters Day 3, Sanofi Buys Bioverativ - 5 Things You Must Know

Shutdown Enters Day 3, Sanofi Buys Bioverativ - 5 Things You Must Know

U.S. stock futures suggest Wall Street will open lower on Monday, as investors watch for the impact of a federal government shutdown that has extended into its third day.

Sanofi Strikes $11.6 Billion Deal for Bioverativ

Sanofi Strikes $11.6 Billion Deal for Bioverativ

France's Sanofi could end its long search for a biotech deal after striking an $11.6 billion offer for Massachusetts-based Bioverativ, a maker of hemophilia treatments.

FCC's Dismantling of Net Neutrality Could Spur New Wave of Telco M&A

FCC's Dismantling of Net Neutrality Could Spur New Wave of Telco M&A

Helped by a relaxed regulatory environment, telco giants could pursue M&A to build and prioritize their own content libraries.

Sanofi Explores Combination Treatments For Multiple Myeloma In New Late-stage Trials

Sanofi Explores Combination Treatments For Multiple Myeloma In New Late-stage Trials

Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment...

Winners and Losers in a Temporary French Tax Revolution

Winners and Losers in a Temporary French Tax Revolution

Some French companies will get a temporary windfall, but others will need to pay more tax.

These 16 Stocks Look Ready to Reverse

These 16 Stocks Look Ready to Reverse

Tesla and General Motors are among this week's names showing reversal patterns.

Sanofi Falls After Third-Quarter Sales Narrowly Miss Forecasts

Sanofi Falls After Third-Quarter Sales Narrowly Miss Forecasts

The French drugmaker's under pressure diabetes treatments slid less than expected but sales of its growing multiple sclerosis products underwhelmed.

Sanofi, Shell and Credit Suisse -- Earnings Round-Up

Sanofi, Shell and Credit Suisse -- Earnings Round-Up

Investors keep an eye on another busy slate of earnings.

Washington Uncertainty and a Healthcare Selloff Send Stocks Lower

Washington Uncertainty and a Healthcare Selloff Send Stocks Lower

Uncertainty in Washington, D.C., a healthcare sector in selloff mode and a big deals day on Wall Street sent U.S. equities lower to begin the week.

Stocks Burrow Further Into the Red on Logistics of Tax Cut Plan

Stocks Burrow Further Into the Red on Logistics of Tax Cut Plan

Stocks dig further into the red on Monday, Oct. 30, as investors weigh how a proposed phase-in corporate tax rate cut might impact U.S. companies.

TheStreet Quant Rating: B (Buy)